SUBSCRIBE
SUBSCRIBE
News   Policy

IsoRay, Inc. Receives No List of Observations (Form FDA 483) in FDA Inspection

July 24, 2008 | 
1 min read
RICHLAND, Wash.--(BUSINESS WIRE)--IsoRay, Inc. (AMEX:ISR) announced today the completion of a baseline inspection by the Food and Drug Administration (FDA) for all its Quality Systems.
Regulatory
MORE ON THIS TOPIC
Yellow warning sign symbol or alert safety danger caution illustration icon security message and exclamation triangle information icon on attention traffic background with secure alarm. 3D render.
Rare diseases
Deaths reported after treatment with Neurocrine’s approved Prader-Willi drug
August 12, 2026
 · 
3 min read
 · 
Annalee Armstrong
FDA
Replimune finally wins approval, Q2 earnings wrap up, psychedelics stay in spotlight
August 12, 2026
 · 
1 min read
 · 
Jef Akst
Cross icon. Reject, decline concept. Hand Mouse Cursor Clicks the Button. Pointer Push Press
Manufacturing
FDA rejects ITM Isotope’s radiopharma therapy over manufacturing issues
August 11, 2026
 · 
1 min read
 · 
Gabrielle Masson
IN PARTNERSHIP WITH AGC BIOLOGICS
From ex vivo to in vivo: Shaping the next generation of viral vector manufacturing
August 10, 2026
 · 
8 min read
 · 
Jennifer C. Smith-Parker